Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,518 questions in 135 reviews · Infectious Diseases
current versionsNo studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Multiple micronutrients vs placebo Hospital admissions · adults with HIV infection (with and without concurrent tuberculosis, with and without ART) Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | RR 0.86 [0.61, 1.22] | 2 studies · 881 participants | Very low |
Zinc vs placebo Change in blood zinc concentrations · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 4 studies · 484 participants | Moderate |
Selenium vs placebo Mortality · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Selenium vs placebo Hospital admissions · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | RR 0.4 [0.21, 0.75] | 1 study · 186 participants | Very low |
Selenium vs placebo Change in CD4 cell count (cells/mm³) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 4 studies · 1187 participants | Low |
Selenium vs placebo Change in viral load (log10copies/mL) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 1 study · 439 participants | Low |
Selenium vs placebo Change in selenium concentrations (µg/L) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 3 studies · 527 participants | Low |
Multiple micronutrients vs placebo CD4 cell count · adults with HIV infection (with and without concurrent tuberculosis, with and without ART) Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 6 studies · 1581 participants | Low |
Multiple micronutrients vs placebo Viral load · adults with HIV infection (with and without concurrent tuberculosis, with and without ART) Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 4 studies · 840 participants | Moderate |
Multiple micronutrients vs placebo Nutritional status · adults with HIV infection (with and without concurrent tuberculosis, with and without ART) Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 3 studies · 1007 participants | Very low |
Vitamin A vs placebo Mortality · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Vitamin A vs placebo Morbidity · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Vitamin A vs placebo CD4 cell count (cells/mm³) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 2 studies · 464 participants | Low |
Vitamin A vs placebo Viral load (log10copies/mL) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 3 studies · 495 participants | Low |
Isoniazid prophylaxis vs placebo Active TB · HIV‐positive children not taking ART Isoniazid for preventing tuberculosis in HIV‐infected children (2017) · Cochrane | HR 0.31 [0.11, 0.87] | 1 study · 240 participants | Low |
Isoniazid prophylaxis vs placebo Death · HIV‐positive children not taking ART Isoniazid for preventing tuberculosis in HIV‐infected children (2017) · Cochrane | HR 0.46 [0.22, 0.95] | 1 study · 240 participants | Low |
Isoniazid prophylaxis vs placebo Active TB · HIV‐positive children on ART Isoniazid for preventing tuberculosis in HIV‐infected children (2017) · Cochrane | RR 0.76 [0.5, 1.14] | 3 studies · 737 participants | Very low |
Isoniazid prophylaxis vs placebo Death · HIV‐positive children on ART Isoniazid for preventing tuberculosis in HIV‐infected children (2017) · Cochrane | RR 1.45 [0.78, 2.72] | 3 studies · 737 participants | Very low |
Mefloquine vs atovaquone‐proguanil Clinical malaria · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | no estimate extracted | 2 studies · 1293 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Vomiting · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 1.31 [0.49, 3.5] | 1 study · 976 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Abdominal pain · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.9 [0.52, 1.56] | 1 study · 976 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Diarrhoea · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.94 [0.6, 1.47] | 1 study · 976 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Headache · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 1.72 [0.99, 2.99] | 1 study · 976 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Dizziness · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 3.99 [2.08, 7.64] | 1 study · 976 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Pruritis · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 1.28 [0.6, 2.7] | 1 study · 976 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Visual impairment · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 2.04 [0.88, 4.73] | 1 study · 976 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Mouth ulcers · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 1.45 [0.7, 3] | 1 study · 976 participants | Ungraded |
Mefloquine vs doxycycline Clinical malaria · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 1.35 [0.35, 5.19] | 4 studies · 744 participants | Ungraded |
Mefloquine vs doxycycline Serious adverse effects · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 1.53 [0.23, 10.24] | 3 studies · 3722 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Serious adverse effects · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 1.4 [0.08, 23.22] | 4 studies · 3693 participants | Ungraded |
Mefloquine vs doxycycline Discontinuations due to adverse effects · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 1.08 [0.41, 2.87] | 4 studies · 763 participants | Ungraded |
Mefloquine vs doxycycline Abnormal dreams · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 10.49 [3.79, 29.1] | 4 studies · 2588 participants | Ungraded |
Mefloquine vs doxycycline Insomnia · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 4.14 [1.19, 14.44] | 4 studies · 3212 participants | Ungraded |
Mefloquine vs doxycycline Anxiety · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 18.04 [9.32, 34.93] | 3 studies · 2559 participants | Ungraded |
Mefloquine vs doxycycline Depressed mood · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 11.43 [5.21, 25.07] | 2 studies · 2445 participants | Ungraded |
Mefloquine vs doxycycline Abnormal thoughts or perceptions · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 6.6 [0.92, 47.2] | 2 studies · 2445 participants | Ungraded |
Mefloquine vs doxycycline Nausea · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.37 [0.3, 0.45] | 5 studies · 2683 participants | Ungraded |
Mefloquine vs doxycycline Vomiting · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.18 [0.12, 0.27] | 4 studies · 5071 participants | Ungraded |
Mefloquine vs doxycycline Abdominal pain · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.3 [0.09, 1.07] | 3 studies · 2536 participants | Ungraded |
Mefloquine vs doxycycline Diarrhoea · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.28 [0.11, 0.73] | 5 studies · 5104 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Discontinuation of drug due to adverse effects · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 2.86 [1.53, 5.31] | 3 studies · 1438 participants | Ungraded |
Mefloquine vs doxycycline Dyspepsia · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.26 [0.09, 0.74] | 5 studies · 5104 participants | Ungraded |
Mefloquine vs doxycycline Headache · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 1.21 [0.5, 2.92] | 5 studies · 3320 participants | Ungraded |
Mefloquine vs doxycycline Dizziness · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 3.49 [0.88, 13.75] | 5 studies · 2633 participants | Ungraded |
Mefloquine vs doxycycline Visual impairment · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 2.37 [1.41, 3.99] | 2 studies · 1875 participants | Ungraded |
Mefloquine vs doxycycline Pruritis · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.52 [0.3, 0.91] | 2 studies · 1794 participants | Ungraded |
Mefloquine vs doxycycline Photosensitivity · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.08 [0.05, 0.11] | 2 studies · 1875 participants | Ungraded |
Mefloquine vs doxycycline Vaginal thrush · Non‐immune adults and children travelling to malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 0.1 [0.06, 0.16] | 1 study · 1761 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Abnormal dreams · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 2.04 [1.37, 3.04] | 1 study · 976 participants | Ungraded |
Mefloquine vs atovaquone‐proguanil Insomnia · non‐immune adults and children travelling to or living in malaria‐endemic settings Mefloquine for preventing malaria during travel to endemic areas (2017) · Cochrane | RR 4.42 [2.56, 7.64] | 1 study · 976 participants | Ungraded |